Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System
Sight Sciences received FDA 510(k) clearance for its next-generation OMNI Ultra Surgical System, designed for canaloplasty and trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The system features implant-free intervention, single-pass canaloplasty, and TruSync Plus technology, building upon the existing OMNI platform which has been utilized in over 350,000 procedures worldwide. The company is preparing for the U.S.
Key figures
- Drug Name
- OMNI Ultra Surgical System
- Launch timing
- fourth quarter of 2026
- Procedures performed
- 350000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.